Out of $700bn in impact investing only 7% goes towards healthcare. But Johnson & Johnson is looking at ways to move the needle.
There is an estimated $700bn of impact investing going on, but only 7% of it is being directed at healthcare — so this is an area with a lot of room for improvement. This was the message from Sarah Hubar-Fisher, senior director of Global External Innovation at pharmaceutical firm Johnson & Johnson at the GCV…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
